Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 379


Heart Failure with Recovered Ejection Fraction in African Americans: Results From the African-American Heart Failure Trial.

Chang KW, Beri N, Nguyen NH, Arbit B, Fox S, Mojaver S, Clopton P, Tam SW, Taylor AL, Cohn JN, Maisel AS, Anand IS.

J Card Fail. 2017 Sep 13. pii: S1071-9164(17)31189-2. doi: 10.1016/j.cardfail.2017.09.005. [Epub ahead of print]


Multinational and multiethnic variations in health-related quality of life in patients with chronic heart failure.

Luo N, Teng TK, Tay WT, Anand IS, Kraus WE, Liew HB, Ling LH, O'Connor CM, Piña IL, Richards AM, Shimizu W, Whellan DJ, Yap J, Lam CSP, Mentz RJ; ASIAN-HF; HF-ACTION investigators.

Am Heart J. 2017 Sep;191:75-81. doi: 10.1016/j.ahj.2017.06.016. Epub 2017 Jul 1.


Eligibility for alirocumab or evolocumab treatment in 1090 hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ≥70 mg/dL despite maximal-tolerated LDL-cholesterol-lowering therapy.

Jetty V, Glueck CJ, Lee K, Goldenberg N, Prince M, Kumar A, Goldenberg M, Anand I, Wang P.

Vasc Health Risk Manag. 2017 Jul 6;13:247-253. doi: 10.2147/VHRM.S133690. eCollection 2017.


Fixed-Dose Versus Off-Label Combination of Isosorbide Dinitrate Plus Hydralazine Hydrochloride: Retrospective Propensity-Matched Analysis in Black Medicare Patients with Heart Failure.

Ofili E, Anand I, Williams RA, Akinboboye O, Xu L, Puckrein G.

Adv Ther. 2017 Jul 13. doi: 10.1007/s12325-017-0584-x. [Epub ahead of print]


Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction: Rationale and Design of the PARAGON-HF Trial.

Solomon SD, Rizkala AR, Gong J, Wang W, Anand IS, Ge J, Lam CSP, Maggioni AP, Martinez F, Packer M, Pfeffer MA, Pieske B, Redfield MM, Rouleau JL, Van Veldhuisen DJ, Zannad F, Zile MR, Desai AS, Shi VC, Lefkowitz MP, McMurray JJV.

JACC Heart Fail. 2017 Jul;5(7):471-482. doi: 10.1016/j.jchf.2017.04.013. Epub 2017 Jun 26. Review.


Physical Activity and Prognosis in the TOPCAT Trial (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist).

Hegde SM, Claggett B, Shah AM, Lewis EF, Anand I, Shah SJ, Sweitzer NK, Fang JC, Pitt B, Pfeffer MA, Solomon SD.

Circulation. 2017 Sep 12;136(11):982-992. doi: 10.1161/CIRCULATIONAHA.117.028002. Epub 2017 Jun 21.


Seattle Heart Failure and Proportional Risk Models Predict Benefit From Implantable Cardioverter-Defibrillators.

Bilchick KC, Wang Y, Cheng A, Curtis JP, Dharmarajan K, Stukenborg GJ, Shadman R, Anand I, Lund LH, Dahlström U, Sartipy U, Maggioni A, Swedberg K, O'Conner C, Levy WC.

J Am Coll Cardiol. 2017 May 30;69(21):2606-2618. doi: 10.1016/j.jacc.2017.03.568.


Role of Biomarkers for the Prevention, Assessment, and Management of Heart Failure: A Scientific Statement From the American Heart Association.

Chow SL, Maisel AS, Anand I, Bozkurt B, de Boer RA, Felker GM, Fonarow GC, Greenberg B, Januzzi JL Jr, Kiernan MS, Liu PP, Wang TJ, Yancy CW, Zile MR; American Heart Association Clinical Pharmacology Committee of the Council on Clinical Cardiology; Council on Basic Cardiovascular Sciences; Council on Cardiovascular Disease in the Young; Council on Cardiovascular and Stroke Nursing; Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation; Council on Epidemiology and Prevention; Council on Functional Genomics and Translational Biology; and Council on Quality of Care and Outcomes Research.

Circulation. 2017 May 30;135(22):e1054-e1091. doi: 10.1161/CIR.0000000000000490. Epub 2017 Apr 26. Review.


Interaction Between Spironolactone and Natriuretic Peptides in Patients With Heart Failure and Preserved Ejection Fraction: From the TOPCAT Trial.

Anand IS, Claggett B, Liu J, Shah AM, Rector TS, Shah SJ, Desai AS, O'Meara E, Fleg JL, Pfeffer MA, Pitt B, Solomon SD.

JACC Heart Fail. 2017 Apr;5(4):241-252. doi: 10.1016/j.jchf.2016.11.015.


Prognostic importance of left ventricular mechanical dyssynchrony in heart failure with preserved ejection fraction.

Biering-Sørensen T, Shah SJ, Anand I, Sweitzer N, Claggett B, Liu L, Pitt B, Pfeffer MA, Solomon SD, Shah AM.

Eur J Heart Fail. 2017 Aug;19(8):1043-1052. doi: 10.1002/ejhf.789. Epub 2017 Mar 21.


Association of quality of life and job stress in occupational workforce of India: Findings from a cross-sectional study on software professionals.

Babu GR, Sudhir PM, Mahapatra T, Das A, Rathnaiah M, Anand I, Detels R.

Indian J Occup Environ Med. 2016 May-Aug;20(2):109-113. doi: 10.4103/0019-5278.197544.


Clinical and Echocardiographic Characteristics and Cardiovascular Outcomes According to Diabetes Status in Patients With Heart Failure and Preserved Ejection Fraction: A Report From the I-Preserve Trial (Irbesartan in Heart Failure With Preserved Ejection Fraction).

Kristensen SL, Mogensen UM, Jhund PS, Petrie MC, Preiss D, Win S, Køber L, McKelvie RS, Zile MR, Anand IS, Komajda M, Gottdiener JS, Carson PE, McMurray JJ.

Circulation. 2017 Feb 21;135(8):724-735. doi: 10.1161/CIRCULATIONAHA.116.024593. Epub 2017 Jan 4.


Necessity of hospitalization and stress testing in low risk chest pain patients.

Beri N, Marston NA, Daniels LB, Nowak RM, Schreiber D, Mueller C, Jaffe A, Diercks DB, Wettersten N, DeFilippi C, Peacock WF, Limkakeng AT, Anand I, McCord J, Hollander JE, Wu AHB, Apple FS, Nagurney JT, Berardi C, Cannon CM, Clopton P, Neath SX, Christenson RH, Hogan C, Vilke G, Maisel A.

Am J Emerg Med. 2017 Feb;35(2):274-280. doi: 10.1016/j.ajem.2016.10.072. Epub 2016 Oct 29.


Prognostic Value of Soluble Suppression of Tumorigenicity-2 in Chronic Heart Failure: A Meta-Analysis.

Aimo A, Vergaro G, Passino C, Ripoli A, Ky B, Miller WL, Bayes-Genis A, Anand I, Januzzi JL, Emdin M.

JACC Heart Fail. 2017 Apr;5(4):280-286. doi: 10.1016/j.jchf.2016.09.010. Epub 2016 Nov 2.


Regional and ethnic differences among patients with heart failure in Asia: the Asian sudden cardiac death in heart failure registry.

Lam CS, Teng TK, Tay WT, Anand I, Zhang S, Shimizu W, Narasimhan C, Park SW, Yu CM, Ngarmukos T, Omar R, Reyes EB, Siswanto BB, Hung CL, Ling LH, Yap J, MacDonald M, Richards AM.

Eur Heart J. 2016 Nov 1;37(41):3141-3153. Epub 2016 Aug 7.


High-Output Heart Failure Revisited.

Anand IS.

J Am Coll Cardiol. 2016 Aug 2;68(5):483-6. doi: 10.1016/j.jacc.2016.05.036. No abstract available.


Heart Failure With Improved Ejection Fraction: Clinical Characteristics, Correlates of Recovery, and Survival: Results From the Valsartan Heart Failure Trial.

Florea VG, Rector TS, Anand IS, Cohn JN.

Circ Heart Fail. 2016 Jul;9(7). pii: e003123. doi: 10.1161/CIRCHEARTFAILURE.116.003123.


Implantable Cardioverter-Defibrillator Use in Patients With Left Ventricular Assist Devices: A Systematic Review and Meta-Analysis.

Vakil K, Kazmirczak F, Sathnur N, Adabag S, Cantillon DJ, Kiehl EL, Koene R, Cogswell R, Anand I, Roukoz H.

JACC Heart Fail. 2016 Oct;4(10):772-779. doi: 10.1016/j.jchf.2016.05.003. Epub 2016 Jul 6.


Prognostic Value of Insulin-Like Growth Factor-Binding Protein 7 in Patients with Heart Failure and Preserved Ejection Fraction.

Gandhi PU, Chow SL, Rector TS, Krum H, Gaggin HK, McMurray JJ, Zile MR, Komajda M, McKelvie RS, Carson PE, Januzzi JL Jr, Anand IS.

J Card Fail. 2017 Jan;23(1):20-28. doi: 10.1016/j.cardfail.2016.06.006. Epub 2016 Jun 16.


Clinical outcomes according to QRS duration and morphology in the irbesartan in patients with heart failure and preserved systolic function (I-PRESERVE) trial.

Cannon JA, Shen L, Jhund PS, Anand IS, Komajda M, McKelvie RS, Zile MR, Carson PE, McMurray JJ.

Eur J Heart Fail. 2016 Aug;18(8):1021-31. doi: 10.1002/ejhf.547. Epub 2016 May 15.

Supplemental Content

Loading ...
Support Center